LUZHU BIOTECH-B (02480) announced its results for the six months ended June 30, 2025, reporting other income of RMB 4.85 million, down 50.2% year-on-year. The company recorded a net loss of RMB 77.57 million, representing a 29.4% narrowing compared to the same period last year. Basic loss per share stood at RMB 0.39.
During the first half of 2025, the company achieved several significant corporate milestones. In January 2025, the Group submitted a Biologics License Application (BLA) for its core product LZ901 to the National Medical Products Administration, which was subsequently accepted in February 2025. According to relevant Chinese laws and regulations, following BLA acceptance, the National Medical Products Administration will conduct further procedures including, but not limited to, technical reviews, clinical trial site inspections, and manufacturing site inspections to evaluate the application. LZ901 can only be commercialized after obtaining BLA approval and batch release certification.
Additionally, during the first half of 2025, the Group successfully completed a head-to-head comparison study for LZ901. The study results demonstrated that compared to the recombinant glycoprotein E subunit vaccine HZ/su (Shingrix®), LZ901 induced superior cellular immune responses and exhibited better safety profiles in adults aged 50 and above. The Board believes these positive outcomes establish a solid foundation for the future commercialization of LZ901.
